Medexus Pharma, Inc.

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

1 in Phase 3

Quick facts

Phase 3 pipeline

APVO101 · Oncology
APVO101 is a dual checkpoint inhibitor that blocks both PD-1 and CTLA-4 pathways to enhance anti-tumor immune responses.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Medexus Pharma, Inc. portfolio CI brief
Medexus Pharma, Inc. pipeline updates RSS

Frequently asked questions about Medexus Pharma, Inc.

What is Medexus Pharma, Inc.'s pipeline?

Medexus Pharma, Inc. has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include APVO101.

Sector hub: All tracked pharma companies